

2012 No. 2791

**NATIONAL HEALTH SERVICE, ENGLAND AND
WALES**

NATIONAL HEALTH SERVICE, SCOTLAND

**HEALTH AND PERSONAL SOCIAL SERVICES,
NORTHERN IRELAND**

**The Health Service Branded Medicines (Control of Prices and
Supply of Information) Amendment Regulations 2012**

<i>Made</i>	- - - -	<i>6th November 2012</i>
<i>Laid before Parliament</i>		<i>9th November 2012</i>
<i>Coming into force</i>	- -	<i>1st January 2013</i>

The Secretary of State for Health makes the following Regulations in exercise of the powers in sections 262(1), 263(1), 266(1)(a) and 272(7) of the National Health Service Act 2006(a).

The Secretary of State has consulted in accordance with sections 262(1) and 263(1) of that Act.

Citation and commencement

1. These Regulations may be cited as the Health Service Branded Medicines (Control of Prices and Supply of Information) Amendment Regulations 2012 and come into force on 1st January 2013.

Amendment of the Health Service Branded Medicines (Control of Prices and Supply of Information) (No. 2) Regulations 2008

2. In regulation 2 of the Health Service Branded Medicines (Control of Prices and Supply of Information) (No. 2) Regulations 2008(b), in paragraphs (1) and (2), for “5.5 per cent” substitute “5.3 per cent”.

Revocation

3. The Health Service Branded Medicines (Control of Prices and Supply of Information) Amendment Regulations 2011(c) are revoked.

(a) 2006 c.41.
(b) S.I. 2008/3258, amended by S.I. 2011/2955.
(c) S.I. 2011/2955.

Signed by authority of the Secretary of State for Health.

6th November 2012

Earl Howe
Parliamentary Under-Secretary of State,
Department of Health

EXPLANATORY NOTE

(This note is not part of the Regulations)

These Regulations, which apply to the United Kingdom, amend regulation 2 of the Health Service Branded Medicines (Control of Prices and Supply of Information) (No.2) Regulations 2008 (“the 2008 Regulations”).

Regulation 2 of the 2008 Regulations specifies the maximum price which may be charged for the presentation of a branded medicine which is supplied for health service purposes, unless the medicine falls within a voluntary scheme for limiting prices or profits or the price is determined under the other provisions of the Regulations. The amendment provides that the maximum price of a presentation is calculated by deducting 5.3 % (instead of 5.5 %) from the price for which that presentation was on sale for health service purposes in England on 1st December 2008. The amendment mirrors a change to the Pharmaceutical Price Regulation Scheme 2009 (available at www.dh.gov.uk), which has effect on 1st January 2013.

An Impact Assessment has been prepared and is available at www.dh.gov.uk. Copies may also be obtained from the Department of Health, Zone 456D, Skipton House, 80 London Road, London SE1 6LH.

© Crown copyright 2012

Printed and published in the UK by The Stationery Office Limited under the authority and superintendence of Carol Tullo, Controller of Her Majesty’s Stationery Office and Queen’s Printer of Acts of Parliament.

£4.00

E4912 11/2012 124912T 19585

ISBN 978-0-11-153053-5



9 780111 530535